No Data
No Data
No Data
No Data
No Data
Edgewise Receives EMA Orphan Drug Designations For Sevasemten For Becker And Duchenne Muscular Dystrophies
Edgewise Receives EMA Orphan Drug Designations For Sevasemten For Becker And Duchenne Muscular Dystrophies
BenzingaApr 23 20:06
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Dow JonesApr 22 23:58
Royal Bank of Canada: Maintaining the Edgewise Therapeutics (EWTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $28.00 to $32.00.
Royal Bank of Canada: Maintaining the Edgewise Therapeutics (EWTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $28.00 to $32.00.
Zhitong FinanceApr 22 23:50
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $28 to $32.
BenzingaApr 22 23:48
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Edgewise Therapeutics (EWTX)
TipRanksApr 22 18:50
Edgewise Therapeutics Earns 'Buy' Rating From Joseph Schwartz on Strong Clinical Data and Promising Drug Prospects
TipRanksApr 18 12:28
No Data
No Data